10-Q/A: Genvor Amends Q1 2026 Report, Cites Going Concern

Genvor Incorporated filed an amendment to its Q1 2026 quarterly report to correct typographical errors and update certifications, while reiterating significant financial challenges including a going concern warning.

Summary

• Genvor Incorporated filed an Amendment No. 1 on Form 10-Q/A to correct two typographical check box errors on the cover page of its Quarterly Report on Form 10-Q for the period ended December 31, 2025, and to include updated certification exhibits.
• The amendment explicitly states it does not reflect events subsequent to the original filing date and does not modify other disclosures, including forward-looking statements, from the original Quarterly Report.
• The company reported no revenues for the three months ended December 31, 2025, or 2024.
• Net loss for the three months ended December 31, 2025, was $(576,280), a significant decrease from $(5,001,251) for the same period in 2024, primarily due to a $4,612,500 decrease in stock-based compensation.
• Operating expenses decreased by 88.7% to $562,655 for the three months ended December 31, 2025, compared to $4,997,414 in the prior year.
• The company had a working capital deficit of approximately $(1,059,320) at December 31, 2025, an improvement from $(1,312,382) at September 30, 2025.
• Cash balance increased to $103,580 at December 31, 2025, from $37,231 at September 30, 2025.
• Net cash used in operating activities was $(193,651) for the three months ended December 31, 2025, compared to $(1,442) for the same period in 2024.
• Management concluded that disclosure controls and procedures were not effective as of December 31, 2025.
• The company continues to face substantial doubt about its ability to continue as a going concern due to recurring net losses, negative operating cash flows, and insufficient cash to support operations for the next twelve months.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a company with promising technology and strategic partnerships, but significant financial instability, a going concern warning, and ineffective internal controls present substantial risks for investors.

Positives

• Net loss significantly decreased by 88.5% to $(576,280) for the three months ended December 31, 2025, compared to $(5,001,251) in the prior year, primarily driven by lower stock-based compensation.
• Loss from operations decreased by 88.7% to $(562,655) for the three months ended December 31, 2025, from $(4,997,414) in the prior year.
• Cash balance increased to $103,580 at December 31, 2025, from $37,231 at September 30, 2025.
• Working capital deficit improved by $253,062, reducing to $(1,059,320) at December 31, 2025, from $(1,312,382) at September 30, 2025.
• Successfully converted a convertible note payable and accrued interest totaling $22,092 into 22,092 shares of common stock.
• Settled a legal claim with Justin Kimbrough, resulting in the return and cancellation of 331,250 shares of common stock.
• Achieved a favorable settlement in the Richard Saied lawsuit, with the court ordering reimbursement of attorney fees and the return of contested shares.
• Awarded the Bayer Golden Ticket in 2024, providing fully funded access to Bayer's LifeHub California laboratories and expert mentorship.
• Maintains a robust intellectual property portfolio with 5 issued U.S. patents, 2 pending U.S. patent applications, and 4 additional applications in preparation, with U.S. patent protection extending through 2038.
• Transgenic corn peptide AGM182 demonstrated a 76-98% reduction in total aflatoxin contamination in published USDA research, with no adverse effects on plant growth or yield and a proven mammalian safety profile.

Negatives

• The company generated no revenues for the three months ended December 31, 2025, or 2024.
• Recurring net losses and negative cash flow from operating activities persist, with a net loss of $(576,280) and $193,651 cash used in operations for the three months ended December 31, 2025.
• Management has identified substantial doubt about the company's ability to continue as a going concern due to insufficient cash to support operations for the next twelve months.
• Disclosure controls and procedures were deemed 'not effective' by management as of December 31, 2025.
• Professional fees increased significantly by 1,545.6% to $191,182 for the three months ended December 31, 2025, primarily due to consulting services paid with common stock and increased legal/accounting fees.
• Other general and administrative expenses increased by 270.9% to $34,899, mainly due to OTC listing fees and increased insurance costs.
• Interest expense related to related parties increased by 255.10% to $15,025.
• An SBA loan of $48,750 from April 2020 remains outstanding, with forgiveness pending.
• A demand letter from former CBO/Interim CFO Judith Miller for alleged owed amounts is being disputed by the company.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring net losses, negative cash flows from operating activities, and insufficient cash to support operations for the next twelve months.
• The company's ability to raise additional capital through debt or future issuances of capital stock is uncertain, with no assurances of success or availability on satisfactory terms.
• Disclosure controls and procedures were not effective as of December 31, 2025, which could impact the reliability and timeliness of financial reporting.
• Ongoing legal proceedings, including a dispute with former CBO/Interim CFO Judith Miller, could result in unforeseen financial liabilities or reputational damage.
• The successful development and commercialization of the company's products and technologies are necessary for its business plan, but there can be no assurances of success.
• Commercialization of products requires regulatory approval from agencies such as the EPA, USDA, and FDA, which is a lengthy and uncertain process.

Future Outlook

The filing explicitly states that this Amendment No. 1 does not modify or update any forward-looking statements from the original Quarterly Report. However, the company expects research and development expenses to increase in the near future as it continues to work on commercializing its products. Advertising and marketing expenses are expected to remain at current quarterly levels with minimal increases. Management intends to raise additional funds through public and/or private offerings to support its business plan and operations.

Management Comments

• "Management intends to raise additional funds by way of additional public and/or private offerings of its stock."
• "Management believes that the actions presently being taken to further implement its business plan, develop its products and technologies, and generate revenues should provide the opportunity for the Company to continue as a going concern."
• "Our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were not effective to provide reasonable assurance of achieving the objectives of timely alerting them to material information required to be included in our periodic SEC reports and of ensuring that such information is recorded, processed, summarized, and reported with the time periods specified."

Industry Context

StockSavvy.ai notes that Genvor operates in the agricultural biotechnology sector, leveraging AI-accelerated peptide technology for sustainable crop protection and plant health. This aligns with broader industry trends towards biological solutions, reduced chemical inputs, and enhanced agricultural productivity. The company's licensing-first strategy and collaborations with institutions like the USDA and industry leaders such as Bayer (via the Golden Ticket award) are common for early-stage biotech firms seeking validation and market access without extensive upfront capital investment. The focus on critical issues like aflatoxin contamination is pertinent to global food security and addresses increasing consumer and regulatory demands for safer, residue-free food products.

Comparison to Industry Standards

• Genvor's transgenic corn peptide AGM182 demonstrating a 76-98% reduction in total aflatoxin contamination in USDA research represents a significant scientific validation, comparable to efficacy benchmarks set by established agricultural biotech companies like Bayer Crop Science (formerly Monsanto) for their genetically modified crop traits targeting specific pests or diseases.
• The Bayer Golden Ticket award positions Genvor among a select group of innovative AgriFoodTech startups, providing access to resources and mentorship from a global leader, similar to how other corporate accelerators or venture programs identify and support promising technologies in the sector.
• The company's intellectual property portfolio, including 5 issued U.S. patents and several pending applications, provides a foundational asset, though its competitive strength relative to the extensive patent portfolios of industry giants like Corteva Agriscience or Syngenta would require detailed legal and market analysis.
• The 'going concern' warning and lack of revenue are typical for early-stage biotechnology companies focused on R&D, but the reported ineffectiveness of disclosure controls is a significant governance concern that deviates from best practices expected of publicly traded companies, regardless of their size or stage of development.

Corporate Governance

Legal Proceedings

• Suit filed against Justin Kimbrough and Prosperity Consultants, LLC, alleging fraud, conversion, and unjust enrichment. A settlement has been reached, requiring Mr. Kimbrough to return a portion of his shares, with 331,250 shares already returned and cancelled.
• Suit filed against Richard Saied, alleging fraud, conversion, and unjust enrichment. The matter was settled in the company's favor on October 29, 2025, with Mr. Saied ordered to reimburse attorney fees and return contested shares, which have not yet been returned.
• Judith Miller, former CBO and Interim CFO, sent a demand letter on October 13, 2024, for alleged owed amounts under her prior employment agreement. The company disputes these allegations and intends to defend itself.

Related Party Transactions

• Accrued compensation and advances from the CEO and two scientific advisors bear interest at 8% per annum.
• Accrued compensation and related expenses owed to the CEO and scientific advisors totaled $715,456 at December 31, 2025.
• Advances owed to scientific advisors totaled $84,137 at December 31, 2025.
• Interest expense with these related parties amounted to $15,025 for the three months ended December 31, 2025.
• The company owed its former chief business officer and interim chief financial officer, Judith Miller, $38,904 primarily from accrued compensation.
• The CEO, Chad Pawlak, receives 250,000 shares of common stock each calendar quarter as compensation pursuant to an amended employment agreement effective January 1, 2025.
• Scientific advisors Dr. Jesse Jaynes and Dr. Clayton Yates receive increased monthly compensation ($9,167 and $8,333 respectively, effective January 1, 2025) and milestone-based compensation including cash and common stock.

Stakeholder Impact

• **Shareholders:** Face potential dilution from future equity capital raises and ongoing stock-based compensation. The 'going concern' warning and ineffective disclosure controls pose significant risks to investment value. However, successful commercialization of technology and strategic partnerships could offer future upside.
• **Employees (Management/Advisors):** Key management and scientific advisors receive substantial compensation, including significant stock awards, and provide working capital advances, indicating a vested interest but also a reliance on their financial support.
• **Creditors:** Exposed to heightened risk due to the company's 'going concern' status, recurring losses, and working capital deficit.
• **Customers/Partners:** Potential for innovative agricultural solutions if Genvor's technology is successfully developed and commercialized. Existing partnerships with USDA and Bayer indicate potential for future product development and market access.

Next Steps

• Continue working on commercializing products and technologies.
• Raise additional funds through public and/or private offerings to support operations.
• Continue multi-year studies with USDA partners on seed traits in corn.
• Explore international animal health research collaborations.
• Intensify efforts in non-GMO product development and expediting the innovation of novel peptides.
• Collaborate with contract manufacturing firms to develop efficient and cost-effective manufacturing systems.
• Execute the settlement terms with Justin Kimbrough, including the return of common stock.
• Await the return of contested shares from Richard Saied as ordered by the court.
• Defend against the demand for payment from Judith Miller.
• Address and remediate the identified ineffectiveness of disclosure controls and procedures.

Key Dates

Recommendation

The company faces severe financial challenges, including a 'going concern' warning, recurring losses, and negative operating cash flow. While it possesses promising technology and strategic partnerships, the lack of revenue, ineffective disclosure controls, and ongoing need for capital raise significant red flags for investors. The amendment itself does not introduce new positive information to offset these fundamental issues, making the stock a high-risk investment with substantial downside potential.

Keywords

Agricultural biotechnology, AI-accelerated peptide technology, Crop protection, Plant health, BioCypher Algorithm, Sustainable agriculture, Going concern, SEC filing, 10-Q/A, Financial reporting, Aflatoxin, USDA, Bayer Golden Ticket